Over the last decade, melanoma survival rates have improved significantly due to ongoing research and the development of immunotherapy. Lifileucel, also known by its brand name AMTAGVI, is a new form of immunotherapy approved by the U.S. Food and Drug Administration (FDA) for patients with metastatic melanoma whose cancer has stopped responding to immune checkpoint inhibitors. The Barbara Ann Karmanos Cancer Institute is the first and only cancer center in Michigan to treat a patient with this new immun...